Nipple-saving breast surgery under the microscope: is it safe for gene carriers?
NCT ID NCT06888388
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 4700 women with high-risk gene mutations (like BRCA1/2) who choose to have a nipple-sparing mastectomy to prevent breast cancer. Researchers want to see if keeping the nipple is safe over many years, compared to traditional mastectomy that removes it. The goal is to provide long-term data to help women and doctors make informed decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nipple-sparing mastectomy (surgery that removes breast tissue but keeps the nipple and skin)
What this could lead to
If successful, this study could confirm that nipple-sparing mastectomy is a safe option for women with high-risk gene mutations, allowing them to reduce cancer risk without sacrificing the nipple.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may take years, and the long follow-up needed means findings are not immediate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER SURGERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital - Dana-Farber Brigham Cancer Center
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
CHU de Quebec Université laval
RECRUITINGQuébec, Quebec, G1S 4L8, Canada
Contact Email: •••••@•••••
Contact
-
Champalimaud Foundation, University of Lisbon
NOT_YET_RECRUITINGLisbon, Portugal
Contact Email: •••••@•••••
Contact
-
Hamilton Health Sciences
RECRUITINGHamilton, Ontario, L8L 2X2, Canada
Contact Email: •••••@•••••
Contact
-
Jewish General Hospital
RECRUITINGMontreal, Quebec, H3T1E2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center (MSKCC)
NOT_YET_RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
-
University of Calgary
RECRUITINGCalgary, Alberta, T2N 4N1, Canada
Contact
Contact Email: •••••@•••••
-
University of Melbourne, Peter MacCallum Cancer Center
NOT_YET_RECRUITINGMelbourne, Australia
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104-6205, United States
Contact Email: •••••@•••••
Contact
-
Women's College Hospital, University of Toronto
NOT_YET_RECRUITINGToronto, Ontario, Canada
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Email: •••••@•••••
Contact
-
Ziekenhuis Aan de Stroom
ACTIVE_NOT_RECRUITINGAntwerp, 2030, Belgium